Literature DB >> 25864863

Lymphoma in acquired generalized lipodystrophy.

Rebecca J Brown1, Jean L Chan2, Elaine S Jaffe3, Elaine Cochran1, Alex M DePaoli4, Jean-Francois Gautier5, Cecile Goujard6, Corinne Vigouroux7,8,9,10, Phillip Gorden1.   

Abstract

Acquired generalized lipodystrophy (AGL) is a rare disease thought to result from autoimmune destruction of adipose tissue. Peripheral T-cell lymphoma (PTCL) has been reported in two AGL patients. We report five additional cases of lymphoma in AGL, and analyze the role of underlying autoimmunity and recombinant human leptin (metreleptin) replacement in lymphoma development. Three patients developed lymphoma during metreleptin treatment (two PTCL and one ALK-positive anaplastic large cell lymphoma), and two developed lymphomas (mycosis fungoides and Burkitt lymphoma) without metreleptin. AGL is associated with high risk for lymphoma, especially PTCL. Autoimmunity likely contributes to this risk. Lymphoma developed with or without metreleptin, suggesting metreleptin does not directly cause lymphoma development; a theoretical role of metreleptin in lymphoma progression remains possible. For most patients with AGL and severe metabolic complications, the proven benefits of metreleptin on metabolic disease will likely outweigh theoretical risks of metreleptin in lymphoma development or progression.

Entities:  

Keywords:  Acquired generalized lipodystrophy; T-cell lymphoma; leptin; metreleptin; mycosis fungoides

Mesh：

Substances：

Year:  2015        PMID： 25864863      PMCID： PMC4755279          DOI： 10.3109/10428194.2015.1040015

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  23 in total

1.  Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.

Authors:  Ken Ebihara; Toru Kusakabe; Masakazu Hirata; Hiroaki Masuzaki; Fumiko Miyanaga; Nozomi Kobayashi; Tomohiro Tanaka; Hideki Chusho; Takashi Miyazawa; Tatsuya Hayashi; Kiminori Hosoda; Yoshihiro Ogawa; Alex M DePaoli; Masanori Fukushima; Kazuwa Nakao
Journal:  J Clin Endocrinol Metab       Date:  2006-11-21       Impact factor: 5.958

2.  Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy.

Authors:  Jean Y Park; Edward D Javor; Elaine K Cochran; Alex M DePaoli; Phillip Gorden
Journal:  Metabolism       Date:  2007-04       Impact factor: 8.694

3.  Peripheral T-cell lymphoma presenting as lipoatrophy and nodules.

Authors:  James A Yiannias; David J DiCaudo; Erik Maskin
Journal:  Int J Dermatol       Date:  2006-12       Impact factor: 2.736

4.  Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects.

Authors:  M Ozata; I C Ozdemir; J Licinio
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

5.  Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy.

Authors:  Elif Arioglu Oral; Edward D Javor; Li Ding; Gulbu Uzel; Elaine K Cochran; Janice Ryan Young; Alex M DePaoli; Steven M Holland; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2005-11-29       Impact factor: 5.958

6.  Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study.

Authors:  M Fallah; X Liu; J Ji; A Försti; K Sundquist; K Hemminki
Journal:  Ann Oncol       Date:  2014-07-31       Impact factor: 32.976

Review 7.  Autoimmune and inflammatory disorders and risk of malignant lymphomas--an update.

Authors:  K E Smedby; J Askling; X Mariette; E Baecklund
Journal:  J Intern Med       Date:  2008-12       Impact factor: 8.989

8.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.

Authors:  Karin Ekström Smedby; Claire M Vajdic; Michael Falster; Eric A Engels; Otoniel Martínez-Maza; Jennifer Turner; Henrik Hjalgrim; Paolo Vineis; Adele Seniori Costantini; Paige M Bracci; Elizabeth A Holly; Eleanor Willett; John J Spinelli; Carlo La Vecchia; Tongzhang Zheng; Nikolaus Becker; Silvia De Sanjosé; Brian C-H Chiu; Luigino Dal Maso; Pierluigi Cocco; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Scott Davis; Richard Severson; James R Cerhan; Elizabeth C Breen; Brenda Birmann; Andrew E Grulich; Wendy Cozen
Journal:  Blood       Date:  2008-02-08       Impact factor: 22.113

9.  Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression.

Authors:  G M Lord; G Matarese; J K Howard; R J Baker; S R Bloom; R I Lechler
Journal:  Nature       Date:  1998-08-27       Impact factor: 49.962

10.  Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.

Authors:  David Araujo-Vilar; Sofía Sánchez-Iglesias; Cristina Guillín-Amarelle; Ana Castro; Mary Lage; Marcos Pazos; José Manuel Rial; Javier Blasco; Encarna Guillén-Navarro; Rosario Domingo-Jiménez; María Ruiz del Campo; Blanca González-Méndez; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-11-04       Impact factor: 3.633
View more
  11 in total

Review 1.  Lipodystrophy syndromes.

Authors:  Pedro Herranz; Raul de Lucas; Luis Pérez-España; Matias Mayor
Journal:  Dermatol Clin       Date:  2008-10       Impact factor: 3.478

2.  Effects of Metreleptin in Pediatric Patients With Lipodystrophy.

Authors:  Rebecca J Brown; Cristina Adelia Meehan; Elaine Cochran; Kristina I Rother; David E Kleiner; Mary Walter; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2017-05-01       Impact factor: 5.958

Review 3.  Treatment Options for Lipodystrophy in Children.

Authors:  Francesca Mainieri; Veronica Maria Tagi; Francesco Chiarelli
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

4.  Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.

Authors:  Rebecca J Brown; Elif A Oral; Elaine Cochran; David Araújo-Vilar; David B Savage; Alison Long; Gregory Fine; Taylor Salinardi; Phillip Gorden
Journal:  Endocrine       Date:  2018-04-12       Impact factor: 3.633

Review 5.  Update on Therapeutic Options in Lipodystrophy.

Authors:  Baris Akinci; Rasimcan Meral; Elif Arioglu Oral
Journal:  Curr Diab Rep       Date:  2018-10-29       Impact factor: 4.810

Review 6.  Severe insulin resistance syndromes.

Authors:  Angeliki M Angelidi; Andreas Filippaios; Christos S Mantzoros
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

7.  Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.

Authors:  Nevin Ajluni; Moahad Dar; John Xu; Adam H Neidert; Elif A Oral
Journal:  J Diabetes Metab       Date:  2016-03-23

Review 8.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

9.  Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin.

Authors:  Nazanene H Esfandiari; Melvyn Rubenfire; Adam H Neidert; Rita Hench; Abdelwahab Jalal Eldin; Rasimcan Meral; Elif A Oral
Journal:  Clin Diabetes Endocrinol       Date:  2019-03-14

Review 10.  Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People

Authors:  Samim Özen; Barış Akıncı; Elif A. Oral
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.